Light-controlled CRISPR–dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications
Advanced Drug Delivery Reviews · 2026-09 · 236 · 115921
DOI: 10.1016/j.addr.2026.115921 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-09. Verfasst von Naiyereh Alipour Eskandani und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Advanced Technologies in Medical, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran. Hauptthemen laut MEDLINE: Epigenome Editing, Neoplasms, Drug Delivery Systems, CRISPR-Cas Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 244 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Cancer is increasingly recognized as a disease of the dysregulated epigenome; however, current epi-drugs are blunt, systemically toxic instruments. Catalytically dead CRISPR nucleases (dCas9) linked to chromatin effectors have now made it possible not only to write and erase epigenetic marks at specified loci without double-strand breaks but also to add an element of optogenetics, or reversible and light-encoded control over the timing and localization of the editors. In this review, the technological underpinnings of light-controlled CRISPR-dCas9 epigenome editing, which include architectures of dCas9 scaffold and guide, blue-to-near-infrared photoswitches, and high-gain epigenetic effector designs, are synthesized, and viral, non-viral, and stimuli-responsive delivery platforms, which have to be co-optimized with clinical light interfaces, are discussed. We then outline four functional routes by which opto-epigenome editors may be used therapeutically in cancer: tumor suppressor reactivation; oncogene and super-enhancer repression with metabolic rewiring; control of cancer stem cell differentiation; and immunomodulation of the tumor microenvironment. Lastly, a translational roadmap is defined in terms of preclinical model tiers, biomarker strategies, regulatory and manufacturing factors, and future directions, including NIR and bioluminescent actuation, implantable μLED devices, and AI-guided closed-loop illumination. Together, these aspects constitute design principles for advancing light-addressable epigenome editors toward first-in-human studies and for integrating them into combination regimens as a new class of precision cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Advanced Technologies in Medical, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran.
- Department of Biology, Faculty of Science, University of Tehran, Tehran 14155-6455, Iran.
- NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea. Electronic address: farani.marzi@inha.ac.kr.
- Faculty of Physics, Shiraz University of Technology, Shiraz, Iran.
- The Center for Energy and Environmental Solutions (CEES), College of STEM-T, South Carolina State University, Orangeburg, SC 29117, USA.
- NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea. Electronic address: h3418kr@inha.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Eskandani, N. A., Mirzaee, D., Ramezani Farani, M., Hatami, A., Hatami, M., Ghasemzaei, M., Ghoreishian, S. M., Hwang, S. K., & Huh, Y. S. (2026). Light-controlled CRISPR–dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications. Advanced Drug Delivery Reviews, 236, 115921. https://doi.org/10.1016/j.addr.2026.115921
Vancouver
Eskandani NA, Mirzaee D, Ramezani Farani M, Hatami A, Hatami M, Ghasemzaei M, et al. Light-controlled CRISPR–dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications. Advanced Drug Delivery Reviews. 2026;236:115921. doi:10.1016/j.addr.2026.115921
BibTeX
@article{Eskandani2026,
author = {Eskandani, Naiyereh Alipour and Mirzaee, Danial and Ramezani Farani, Marzieh and Hatami, Afrooz and Hatami, Mohsen and Ghasemzaei, Maryam and Ghoreishian, Seyed Majid and Hwang, Seung-Kyu and Huh, Yun Suk},
title = {Light-controlled CRISPR–dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {236},
pages = {115921},
doi = {10.1016/j.addr.2026.115921}
}
EUVIMED